Navigation Links
Study Identifies Mechanism Which May Help Tamoxifen Work Better

The “crosstalk” between estrogen and a special protein responsible for cell development (Notch) helps breast cancer cells// proliferate and spread, a new study shows.

“Breast cancer cells respond to loss of estrogen, which is caused by commonly used hormonal therapy, by increasing the Notch signal,” said senior study investigator Dr. Lucio Miele, professor, departments of pathology, pharmacology and experimental therapeutics, Loyola University Chicago Stritch School of Medicine, Maywood, Ill. “This helps the cancer cells survive the loss of estrogen.

“Blocking the Notch pathway with a Notch inhibitor offers a new strategy to stopping breast cancer,” said Miele, director, breast cancer basic science program, Cardinal Bernardin Cancer Center, Loyola University Health System. He presented the findings here today at the 29th annual San Antonio Breast Cancer Symposium.

Notch inhibitors are currently in early human clinical trials.

“Results of our study shows that in estrogen receptor positive cancers, a drug which inhibits the Notch protein should be used in combination with estrogen inhibitors,” said Miele. “In estrogen receptor negative cancers, the Notch inhibitor can be used alone or with chemotherapy.”

A significant number of people currently become resistant to the breast cancer drug tamoxifen. “For tamoxifen to work better, you need to inhibit the Notch pathway,” said co-author Dr. Kathy S. Albain, professor, division of hematology/oncology, department of medicine, Loyola University Chicago Stritch School of Medicine.

“This can be done by using a novel drug to block the Notch pathway while simultaneously controlling estrogen signaling through the estrogen receptor,” said Albain, director, thoracic oncology clinical research program; director, breast clinical research program; and co-director, multidisciplinary breast oncology center; Loyola University Health System, Maywood, Ill.

Albain also said this research suggests new therapeutic strategies for women with breast cancer.

Source-Nwswise
SRM
'"/>




Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Leading pediatric oncology ... in Washington, D.C., for the 49th Congress of the International Society of Paediatric ... President of the Center for Cancer and Blood Disorders at Children’s National, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), ... software tool, and the Cancer Patient Education Network (CPEN), an independent professional organization ... a new strategic alliance. , As CPEN’s strategic partner, HLI will help ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company ... destruction of targeted tissues, announced three leadership team developments today:   ... PhD ... ... Veteran medical device executive Josh ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... , Sept. 12, 2017  Consumer reviews on the independent review ... as the number one company for hearing aids, ranking it higher ... other brands. ... Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high performance, state-of-the-art, ...
Breaking Medicine Technology: